Abstract
Rethinking glioma treatment strategy.
Highlights
Over the past decade, deep molecular analysis has revealed that many cancers, including glioblastomas (GBMs), can be subdivided in several subtypes according to genetic and/or transcriptomal similarity
Given that there are druggable canonic mutations such as EGFR and PDGFRA enriched in specific subtypes, one would think that these mutation(s) should be possible candidates for subtypespecific molecular target therapy
Which subtype we should target for patient at the border between subtypes or with multiple subtypes? recent cumulative evidences suggest that the distinction between molecular GBM subtypes is not necessarily robust, rather variable throughout entire process of tumor formation
Summary
Deep molecular analysis has revealed that many cancers, including glioblastomas (GBMs), can be subdivided in several subtypes according to genetic and/or transcriptomal similarity. These subtype classifications have given significant insight into tumor biology and provided encouragement for targeted therapeutic strategies. Given that there are druggable canonic mutations such as EGFR and PDGFRA enriched in specific subtypes, one would think that these mutation(s) should be possible candidates for subtypespecific molecular target therapy.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
